D-0648-2020 Class II Terminated
FDA drug recall D-0648-2020 was initiated by Appco Pharma LLC on Jan 7, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API The recall status is terminated (terminated Apr 24, 2020). Affected quantity: 1,632 bottes.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 15, 2020
- Initiation Date
- Jan 7, 2020
- Termination Date
- Apr 24, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,632 bottes
Product description
Ranitidine Capsules 300 mg, 30 count bottles. Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623, NDC 62559-691-30.
Reason for recall
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Distribution pattern
Product was distributed to 6 major distributors/wholesalers some with multiple locations who may have further distribute the product.
Code information
Batch # 1905227UE, exp. date Apr-2021 1905228UE, exp. date Apr-2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0648-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026